{"entity":{"id":"athna-biotech","kind":"company","name":"Athna Biotech","aka":["Athna Biotech, Inc.","ATHNA BIOTECH, INC."],"tldr":"Athna Biotech develops nanomedicines, tiny drug-carrying particles, including one for early bladder cancer and one activated by radiotherapy for lung cancer. Both are in laboratory development.","summary":"Athna Biotech develops nanomedicine and drug delivery platforms and carries them through preclinical development. Its news page records NCI awards to develop a salt-based nanomedicine for non-muscle invasive bladder cancer. In fiscal year 2026 NCI awarded it USD 937,492 under STTR award 2R42CA262399-02 for the bladder cancer nanomedicine and USD 1,098,560 under STTR award 5R42CA257584-03 for a radiation-activatable nanoparticle for lung cancer.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://athnabiotech.com/"},{"label":"NIH RePORTER: STTR award 2R42CA262399-02","url":"https://reporter.nih.gov/project-details/11314266"},{"label":"NIH RePORTER: STTR award 5R42CA257584-03","url":"https://reporter.nih.gov/project-details/11399125"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["radiation"],"technologies":["radiodynamic-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No named product on the company website. Read on athnabiotech.com and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"Athens, GA","country":"US","companyType":"biotech","website":"https://athnabiotech.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":937492,"source":"https://reporter.nih.gov/project-details/11314266","note":"NCI STTR award (R42) 2R42CA262399-02: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer"},{"round":"Grant","year":2026,"amountUsd":1098560,"source":"https://reporter.nih.gov/project-details/11399125","note":"NCI STTR award (R42) 5R42CA257584-03: Development of a radiation-activatable nanoparticle for lung cancer therapy"}]},"route":"/companies/athna-biotech/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"technology":[{"id":"radiodynamic-therapy","kind":"technology","name":"Radiodynamic therapy and radiosensitising nanoparticles","route":"/technologies/radiodynamic-therapy/"},{"id":"sonodynamic-therapy","kind":"technology","name":"Sonodynamic therapy","route":"/technologies/sonodynamic-therapy/"}]}}